XML 22 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Disaggregation of Revenues and Concentration Risk
 9 Months Ended
Sep. 30, 2021
Disaggregation Of Revenues And Concentration Risk  
Disaggregation of Revenues and Concentration Risk

7. Disaggregation of Revenues and Concentration Risk

 

The following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater than ten percent of consolidated revenues:

 Schedule of Consolidated Revenues Generated by Unaffiliated Customers

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
Medicare for DetermaRx   23%   35%   23%   27%
Medicare Advantage for DetermaRx   16%    *     17%    *  
Pharma services Company A    *      *      *     21%
Pharma services Company B    *     28%    *     22%
Pharma services Other   26%   26%   11%   27%
Licensing - Company D    *      *     25%    *  
Licensing - Company B   26%    *     12%    *  

 

* Less than 10%

 

The following table presents the percentage of consolidated revenues by products or services classes:

 Schedule of Consolidated Revenues Attributable to Products or Services

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
DetermaRx   41%   37%   40%   31%
Pharma Services   29%   63%   23%   69%
Licensing   30%   -    37%   - 
Total   100%   100%   100%   100%

 

The following table presents the percentage of consolidated revenues attributable to geographical locations:

 Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
United States   61%   63%   41%   56%
Outside of the United States – Pharma Services   9%   37%   22%   44%
Outside of the United States – Licensing   30%   -    37%   - 
Total   100%   100%   100%   100%

 

 

The following table presents Oncocyte’s total accounts receivable from third-party payers and other customers at September 30, 2021 and December 31, 2021.

 Schedule of Accounts Receivable from Third Party and Other Customers

   September 30, 2021   December 31, 2020 
Medicare for DetermaRx™  $148   $91 
Medicare Advantage for DetermaRx™   597    - 
Pharma Services and other   287    112 
Total  $1,032   $203 

 

As of December 31, 2020, our accounts receivable were $0.2 million. During the nine months ending September 30, 2021, our accounts receivable increased by $4.1 million for revenues recognized, offset by cash collected of approximately $2.7 million and $0.5 million of deferred revenue recognized (see Notes 2 and 3).

 

The following table presents accounts receivable, as a percentage of total consolidated accounts receivables, from third-party payers and other customers that provided in excess of 10% of Oncocyte’s total accounts receivable.

 Schedule of Percentage of Total Consolidated Accounts Receivables

   September 30, 2021   December 31, 2020 
Medicare for DetermaRx™   14%   45%
Medicare Advantage for DetermaRx™   58%   * 
Pharma Services Company A   *    35%